IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...
Corporation (NASDAQ: UTHR) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a pioneering clinical trial of its gene-edited xenotransplantation kidney, named UKidney, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback